Just over 2 weeks ago, we announced the launch of Cobroxin, a pain reliever developed by our subsidiary, ReceptoPharm.  Since making that announcement, we have been inundated with calls and emails asking us about Cobroxin and our launch strategy. To help answer these questions, I have put together the following list of some of the most popular questions people have been asking us:

What is Cobroxin?

Cobroxin is the first over-the-counter pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. It is primarily intended to help with lower back pain, migraines, neck aches, shoulder pain, cramps, neuralgia, joint pain and pain associated with repetitive stress and arthritis.

How is Cobroxin different than Tylenol and prescription pain medicine?

Cobroxin is a new type of pain reliever that does not rely on acetaminophen or opiates for its pain relieving effects. Instead, Cobroxin uses a novel mechanism of action that Nutra Pharma’s drug discovery subsidiary, ReceptoPharm, has been studying for the past 10 years – a peptide from cobra venom.

Is it odd to use venom in medicine?

While at first glance, it might seem odd to use cobra venom for pain relief, however, it is not uncommon to see venoms used in medicine. In fact, there are several drugs that use venoms, including a Type 2 Diabetes drug, Byetta, formulated from the poisonous saliva of the Gila monster, and a heart drug, Aggrastat, that is based on proteins from the African saw-scaled viper.

Have pharmaceutical companies approached you about Cobroxin?

Over the past 12 months, we have been approached by several large pharmaceutical companies based here in the United States and abroad. Most of these firms are primarily interested in our research on Multiple Sclerosis (MS) and Adrenomyeloneuropathy (AMN), however, this interest may shift towards pain as we move forward with our Cobroxin launch.

Are there any patents protecting Cobroxin?

Nutra Pharma, ReceptoPharm and Designer Diagnostics own patents protecting their various products. For a more specific answer about Cobroxin, I would refer you to a recent press release from Nutra Pharma entitled “Nutra Pharma Subsidiary, ReceptoPharm, Files Patent Application for the Oral Delivery of Cobra Venom for the Treatment of Pain“.

When will Cobroxin be available and where will it be sold?

We plan to introduce Cobroxin through retailers across the country and are continuing to work diligently to place Cobroxin on retail shelves as quickly as possible. We expect Cobroxin will be available at several leading retailers as early as October.

What type of response have you received from retailers?

The response from retailers has been overwhelmingly positive. For instance, in August, we attended the Efficient Collaborative Retail Marketing conference in Miami, Florida. Each year, this show draws the largest and most well respected retailers from across the country. At this show, we won “Best New Product”, an award selected by the conference attendees, which included many of the major national retailers. Receiving this award was confirmation that retailers believe in Cobroxin.

How much will Cobroxin cost?

Cobroxin will have a suggested retail price of $18.99 for the oral spray and $19.95 for the topical gel, making it one of the most affordable analgesics for moderate to severe chronic pain.

Are you distributing Cobroxin or have you licensed the product to another company?

We recently finalized a key licensing agreement with XenaCare Holdings, which grants them the exclusive rights to distribute Cobroxin in the United States. XenaCare Holdings has continued to commit significant time, financial resources and industry expertise towards the launch of Cobroxin.

Is Cobroxin FDA Approved?

Cobroxin does not require FDA approval because it falls within the regulatory environment of the United States Homeopathic Pharmacopoeia. Unlike most homeopathic medicines, however, the efficacy and safety of Cobroxin is supported by significant clinical evidence including over 46 human clinical studies documenting the use of cobra venom as a pain reliever. Click here for a list of these clinical studies.

Has anyone been using this product already, and if so, how successfully?

We had a limited supply of Cobroxin manufactured, which we then distributed to friends and family. So far, we have received positive reports of Cobroxin helping with knee pain, back pain, shoulder pain and general chronic pain, even for those who have been unsuccessful with other pain medication. This gives us added confidence as we move forward with the national launch.

Can you elaborate on the future products that were mentioned in the press release from August 24th?

For those who have not read that press release, it made a brief comment that we are continuing to finalize formulations for a prescription-only analgesic and a pain reliever for the veterinary market. We have always planned to have a prescription-only analgesic and initially considered launching that before the over-the-counter (OTC) version. Because we are launching Cobroxin as an OTC first, it is likely that a prescription-only analgesic will be our next product coming to market.

Additionally, we have always had an interest in animal health. Originally, our focus was on antiviral medicines, such as the treatment we are developing for Feline Leukemia. Nonetheless, we believe that the opportunity exists for an affordable pain reliever for this market and we plan to pursue that in the near-term.

How can I learn more about Cobroxin?

If you have an interest in learning more about Cobroxin, be sure to visit the product website at http://www.Cobroxin.com. Additionally, I invite you to click here to register for an upcoming online presentation I am giving about the science behind Cobroxin.

With all of the news and excitement surrounding Cobroxin, it is important for us to stress that we are committed to continuing our research on Adrenomyeloneuropathy (AMN), Multiple Sclerosis (MS), HIV, and Hepatitis C. This is important research and, while we are in the midst of our first product launch, our focus on developing treatments for these other indications has not wavered.

In closing, I would like to remind those who have an interest in following Nutra Pharma’s progress to sign up for our E-Alerts. This will provide you with the most recent news, announcements and blog postings from our company.

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Cobroxin – Our Over-the-Counter (OTC) Treatment for Chronic Pain", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

               

4 Comments

THANKS
I have MS and hopefully this will help with neuro pain

Let’s make the next announcement advancements in the cure/reversal of symptoms in MS

Comment by Margaret Terrano — September 8, 2009 @ 1:52 pm

This sounds great. I’ve been waiting for something like this for +9 years. I have fibromyalgia and back pain. I’m looking at investing in the company ,small invester.
Good luck.
Joe.
jlslms@comcast.net.

Comment by Joe Shurtleff — September 8, 2009 @ 5:05 pm

By all accounts this is an amazing product.

I’ve known Rik Deitsch for over 10 years and he is a brilliant biochemist with a great sense for business. Another great attribute he has is the ability to take dry complex information an make it easily understood by the general public with a sense of humor.

Truly an outstanding individual with a great company. I can only expect more great products in the future.

Comment by Doug Danielson — September 11, 2009 @ 12:33 pm

I have been using it for back pain and feel better, but is there any side effects

Comment by Theda Fitzgerald — April 2, 2010 @ 3:19 pm

RSS feed for comments on this post.

TrackBack URL

Leave a Comment

Name (required)

Email (will not be published) (required)

Website